With ResMed, you won’t need to walk the therapy journey alone. We’re here to offer help and support along the way, so you can get the most out of your ResMed product.
* ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.
Share this Page
Coronavirus: Stay informed
ResMed is closely monitoring and responding to the COVID-19 pandemic; the health and safety of our people, customers, business partners; and those who use our products and solutions worldwide is our top priority. Read more here.